NCT01666327View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Inflammatory Bowel Disease
Interventions
DRUG

MT-1303

Trial Locations (1)

Unknown

Research Site, Nottingham

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY